Diffuse large B-cell lymphoma with concomitant c-MYC and BCL6 gene rearrangements with primary skin involvement: A case report and a review of literature


Cite item

Full Text

Abstract

Double-hit lymphoma (DHL) is a rare aggressive B-cell lymphoma with concomitant c-MYC, BCL2 or BCL6 gene rearrangements, which is characterized by the high frequency of extranodal lesions and by resistance to chemotherapy. The median survival does not exceed 18 months in patients with this disease. The majority of DHL is represented by с-MYC/BCL2 cases. The combination of c-MYC/BCL6 occurs rarely (5—8%). The paper describes a case of DHL with concomitant c-MYC and BCL6 gene rearrangements, which mimics diffuse large B-cell lymphoma, leg-type.

About the authors

N G Gabeeva

ФГБУ «Гематологический научный центр» Минздрава России

Москва, Россия

D A Koroleva

ФГБУ «Гематологический научный центр» Минздрава России

Москва, Россия

A V Belyaeva

ФГБУ «Гематологический научный центр» Минздрава России

Москва, Россия

N G Chernova

ФГБУ «Гематологический научный центр» Минздрава России

Москва, Россия

L A Kuzmina

ФГБУ «Гематологический научный центр» Минздрава России

Москва, Россия

A B Sudarikov

ФГБУ «Гематологический научный центр» Минздрава России

Москва, Россия

T N Obukhova

ФГБУ «Гематологический научный центр» Минздрава России

Москва, Россия

A M Kovrigina

ФГБУ «Гематологический научный центр» Минздрава России

Москва, Россия

E E Zvonkov

ФГБУ «Гематологический научный центр» Минздрава России

Москва, Россия

V G Savchenko

ФГБУ «Гематологический научный центр» Минздрава России

Москва, Россия

References

  1. Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708. https://doi.org/10.1182/blood-2006-11-051672
  2. Swerdlow SH, Campo E, Harris NL, Jaffe, ES, Pileri, SA, Stein, H, Thiele, J, Vardiman, JW. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2008.
  3. Barrans S, Crouch S, Smith A, Turner K, Owen R, Patmore R, Roman E, Jack A. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol. 2010;28:3360-3365. https://doi.org/10.1200/JCO.2009.26.3947
  4. Sietse M. Aukema, Reiner Siebert, Ed Schuuring, Gustaaf W. van Imhoff, Hanneke C. Kluin-Nelemans, Evert-Jan Boerma and Philip M. Kluin. Double-hit B-cell lymphomas. Blood. 2011; 117:2319-2331. https://doi.org/10.1182/blood-2010-09-297879
  5. Звонков Е.Е. Первичные экстранодальные В-клеточные лимфатические опухоли: клиника, диагностика, лечение. Дисс. ... д-ра мед. наук. М.; 2009. Ссылка активна на 11.12.2016. Доступно по: www.dissercat.com
  6. Bradford PT1, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood. 2009;113(21):5064-5073. https://doi.org/10.1182/blood-2008-10-184168
  7. Rein Willemze, Elaine S. Jaffe, Gu¨nter Burg, Lorenzo Cerroni, Emilio Berti, Steven H. Swerdlow, Elisabeth Ralfkiaer, Sergio Chimenti, Jose´ L Diaz-Perez, Lyn M Duncan, Florent Grange, Nancy Lee Harris, Werner Kempf, Helmut Kerl, Michael Kurrer, Robert Knobler, Nicola Pimpinelli, Christian Sander, Marco Santucci, Wolfram Sterry, Maarten H Vermeer, Janine Wechsler, Sean Whittaker, Chris JLM Meijer. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768-3785. https://doi.org/10.1182/blood-2004-09-3502
  8. Wilcox RA. Cutaneous B-cell lymphomas: 2015 update on diagnosis, risk-stratification, and management. Am J Hematol. 2015;90(1):73-76. https://doi.org/10.1002/ajh.23863
  9. Илюшкина Е.А., Ковригина А.М., Кравченко С.К., Обухова Т.Н., Воробьев В.И., Звонков Е.Е., Ротанова М.Н., Лапин В.А. Лорие Ю.Ю. Лимфома из клеток мантийной зоны с первичным поражением кожи: клиническое наблюдение. Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2012;5(2):129-134.
  10. Willemze R, Meijer CJ, Scheffer E, Kluin PM, Van Vloten WA, Toonstra J, Van der Putte SC. Diffuse large cell lymphomas of follicle center cell origin presenting in the skin: a clinicopathologic and immunologic study of 16 patients. Am J Pathol. 1987;126:325-333. PMCID: PMC1899577
  11. Grange F, Bekkenk MW, Wechsler J, Meijer CJ, Cerroni L, Bernengo M, Bosq J, Hedelin G, Fink Puches R, van Vloten WA, Joly P, Bagot M, Willemze R. Prognostic factors in primary cutaneous large B-cell lymphomas: A European multicenter study. J Clin Oncol. 2001;19:3602-3610. PMID: 11504742
  12. Senff NJ, Hoefnagel JJ, Jansen PM, Vermeer MH, van Baarlen J, Blokx WA, Canninga-van Dijk MR, Geerts ML, Hebeda KM, Kluin PM, Lam KH, Meijer CJ, Willemze R. Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. J Clin Oncol. 2007;25:1581-1587. https://doi.org/10.1200/JCO.2006.09.6396
  13. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-511. https://doi.org/10.1038/35000501
  14. Juliette J Hoefnagel, Remco Dijkman, Katia Basso, Patty M Jansen, Christian Hallermann, Rein Willemze, Cornelis P Tensen and Maarten H Vermeer. Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood. 2005;105:3671-3678. https://doi.org/10.1182/blood-2004-04-1594
  15. Koens L, Zoutman WH, Ngarmlertsirichai P, Przybylski GK, Grabarczyk P, Vermeer MH, Willemze R, Jansen PM, Schmidt CA, Tensen CP. Nuclear factor-kappaB pathway-activating gene aberrancies in primary cutaneous large B-cell lymphoma, leg type. J Invest Dermatol. 2014;134:290-292. https://doi.org/10.1038/jid.2013.265
  16. Vibha Thomas, Robin Dobson, Robert Mennel. Primary cutaneous large B-cell lymphoma, leg type. Proc (Bayl Univ Med Cent). 2011;24(4):350-353. PMCID: PMC3205164
  17. Swerdlow SH1, Quintanilla-Martinez L, Willemze R, Kinney MC. Cutaneous B-cell lymphoproliferative disorders: report of the 2011 Society for Hematopathology/European Association for Haematopathology workshop. Am J Clin Pathol. 2013;139(4):515-535. https://doi.org/10.1309/AJCPNLC9NC9WTQYY
  18. Gaidano G, Carbone A. MUM1: a step ahead toward the understanding of lymphoma histogenesis. Leukemia. 2000;14(4):563-566. PMID: 10764139
  19. Tunyaplin C, Shaffer AL, Angelin-Duclos CD, Yu X, Staudt LM, Calame KL. Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation. J Immunol. 2004;173:1158-1165. PMID: 15240705
  20. Shaffer AL, Lin KI, Kuo TC, Yu X, Hurt EM, Rosenwald A, Giltnane JM, Yang L, Zhao H, Calame K, Staudt LM. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B-cell gene expression program. Immunity. 2002. PMID: 12150891
  21. Hoefnagel JJ, Mulder MM, Dreef E, Jansen PM, Pals ST, Meijer CJ, Willemze R, Vermeer MH. Expression of B-cell transcription factors in primary cutaneous B-cell lymphoma. Mod Pathol. 2006;19(9):1270-1276. https://doi.org/10.1038/modpathol.3800650
  22. Kodama K, Massone C, Chott A, Metze D, Kerl H, Cerroni L. Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients. Blood. 2005;106(7):2491-2497. https://doi.org/10.1182/blood-2005-03-1175
  23. Juliette J Hoefnagel, Remco Dijkman, Katia Basso, Patty M Jansen, Christian Hallermann, Rein Willemze, Cornelis P Tensen, Maarten H Vermeer, Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood. 2005;105(9). https://doi.org/10.1182/blood-2004-04-1594
  24. Koh J, Enders GH, Dynlacht BD, Harlow E. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature. 1995;375(6531):506-510. https://doi.org/10.1038/375506a0
  25. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA. Role of the INK4a locus in tumor suppression and cell mortality. Cell. 1996;85(1):27-37. PMID: 8620534
  26. Dijkman R, Tensen CP, Jordanova ES, Knijnenburg J, Hoefnagel JJ, Mulder AA, Rosenberg C, Raap AK, Willemze R, Szuhai K, Vermeer MH, Array-based comparative genomic hybridization analysis reveals recurrent chromosomal alterations and prognostic parameters in primary cutaneous large B-cell lymphoma. J Clin Oncol. 2006;24(2):296-305. https://doi.org/10.1200/JCO.2005.02.0842
  27. Ngo VN1, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, Kohlhammer H, Xu W, Yang Y, Zhao H, Shaffer AL, Romesser P, Wright G, Powell J, Rosenwald A, Muller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Staudt LM. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470. https://doi.org/10.1038/nature09671
  28. Pham-Ledard A, Beylot-Barry M, Barbe C, Leduc M, Petrella T, Vergier B, Martinez F, Cappellen D, Merlio JP, Grange F. High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type. JAMA Dermatol. 2014. https://doi.org/10.1001/jamadermatol.2014.821
  29. Rovira J, Karube K, Valera A, Colomer D, Enjuanes A, Colomo L, Martinez-Trillos A, Gine E, Dlouhy I, Magnano L, Delgado J, Martinez A, Villamor N, Campo E, Lopez-Guillermo A. MYD88 L265P mutations, but no other variants, identify a subpopulation of DLBCL patients of activated B-cell origin, extranodal involvement and poor outcome. Clin Cancer Res. 2016 Jan 20. https://doi.org/10.1158/1078-0432.CCR-15-1525
  30. Belaud-Rotureau MA, Marietta V, Vergier B, Mainhaguiet G, Turmo M, Idrissi Y, Ferrer J, Beylot-Barry M, Dubus P, Merlio JP. Inactivation of p16INK4a/CDKN2A gene may be a diagnostic feature of large B cell lymphoma leg type among cutaneous B cell lymphomas. Virchows Arch. 2008;452(6):607-620. https://doi.org/10.1007/s00428-008-0593-x
  31. Sarah Menguy, Audrey Gros, Anne Pham-Ledard, Maxime Battistella, Nicolas Ortonne, François Comoz, Brigitte Balme, Vanessa Szablewski, Laurence Lamant, Agnès Carlotti, Marie-Hélène Lorton, Anne de Muret, François Le Gall, FrédéricFranck, Anne Croue, David Cappellen, Marie Beylot-Barry, Jean-Philippe Merlio, Béatrice Vergier. MYD88 somatic mutation is a diagnostic criterion in primary cutaneous large B-cell lymphoma. The Journal of Investigative Dermatology. 2016. https://doi.org/10.1016/j.jid.2016.04.018
  32. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, Kohlhammer H, Xu W, Yang Y, Zhao H, Shaffer AL, Romesser P, Wright G, Powell J, Rosenwald A, Muller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Staudt LM. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011; 470(7332):115-119. https://doi.org/10.1038/nature09671
  33. Horn H, Ziepert M, Becher C, Barth TFE, Bernd H-W, Feller AC, Klapper W, Hummel M, Stein H, Hansmann M, Schmelter C, M¨oller P, Cogliatti S, Pfreundschuh M, Schmitz N, Tr¨umper L, Siebert R, Loeffler M, Rosenwald A, Ott G. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood. 2013;21(2). https://doi.org/10.1182/blood-2012-06-435842
  34. Hallermann C, Kaune KM, Gesk S, Martin-Subero JI, Gunawan B, Griesinger F, Vermeer MH, Santucci M, Pimpinelli N, Willemze R, Siebert R, Neumann C. Molecular Cytogenetic Analysis of Chromosomal Breakpoints in the IGH, MYC, BCL6, and MALT1 Gene Loci in Primary Cutaneous B-cell Lymphomas. Journal of Investigative Dermatology. 2004;123:213-219. https://doi.org/10.1111/j.0022-202X.2004.22720.x
  35. Friedberg JW. Double-hit diffuse large B-cell lymphoma. J Clin Oncol. 2012;30:3439-3443. https://doi.org/10.1200/JCO.2012.43.5800
  36. Sandlund JT, Kastan MB, Kennedy W, Behm F, Entrekin E, Pui CH, Kalwinsky DT, Raimondi SC. A subtle t(3;8) results in plausible juxtaposition of MYC and BCL6 in a child with Burkitt lymphoma/leukemia and ataxia-telangiectasia. Cancer Genet Cytogenet. 2006;168(1):69-72. https://doi.org/10.1016/j.cancergencyto.2005.12.013
  37. Wang HY, Bossler AD, Schaffer A, Tomczak E, DiPatri D, Frank DM, Nowell PC, Bagg A. A novel t(3;8)(q27;q24.1) simultaneously involving both the BCL6 and MYC genes in a diffuse large B-cell lymphoma. Cancer Genet Cytogenet. 2007;172(1):45-53. https://doi.org/10.1016/j.cancergencyto.2006.07.016
  38. Sanders L, Jayne S, Kennedy B, Miall F, Aukema SM, Siebert R, Wagner SD, Dyer MJ. A Double Hit CD10-Negative B-Cell Lymphoma with t(3;8)(q27;q24) Leading to Juxtaposition of the BCL6 and MYC Loci Associated with Good Clinical Outcome. Case Rep Hematol. 2014;2014:120714. https://doi.org/10.1155/2014/120714
  39. Pillai RK, Sathanoori M, Van Oss SB, Swerdlow SH. Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas. Am J Surg Pathol. 2013;37(3):323-332. https://doi.org/10.1097/PAS.0b013e31826cebad
  40. Karlsson A, Deb-Basu D, Cherry A, Turner S, Ford J, Felsher DW. Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression. Proc Natl Acad Sci USA. 2003;100(17):9974-9979. https://doi.org/10.1073/pnas.1732638100
  41. Le Gouill S, Talmant P, Touzeau C, Moreau A, Garand R, Juge-Morineau N, Gaillard F, Gastinne T, Milpied N, Moreau P, Harousseau JL, Avet-Loiseau H. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica. 2007;92(10):1335-1342. https://doi.org/10.3324/haematol.11305
  42. Li S, Lin P, Fayad LE, Lennon PA, Miranda RN, Yin CC, Lin E, Medeiros LJ. B-cell lymphomas with MYC/8q24 rearrangements and IGH/BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Mod Pathol. 2012;25(1):145-156. https://doi.org/10.1038/modpathol.2011.147
  43. Aukema SM, Kreuz M, Kohler CW, Rosolowski M, Hasenclever D, Hummel M, Kuppers R, Lenze D, Ott G, Pott C, Richter J, Rosenwald A, Szczepanowski M, et al. Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma. Haematologica. 2014;99:726-735. https://doi.org/10.3324/haematol.2013.091827
  44. Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemeister FB, Fowler N, Wang M, Fanale MA, Nastoupil L, Samaniego F, Lee HJ, Dabaja BS, Pinnix CC, Medeiros LJ, Nieto Y, Khouri I, Kwak LW, Turturro F, Romaguera JE, Fayad LE, Westin JR. Double-hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014;166:891-901. https://doi.org/10.1111/bjh.12982
  45. Qing Ye, Xu-Monette ZY, Tzankov A, Deng L, Wang X, Manyam GC, Visco C, Montes-Moreno S, Zhang L, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Parsons BM, Møller MB, Piris MA, Winter JN, Medeiros LJ, Hu S, Young KH. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. Oncotarget. 2016;7(3):2401-2416. https://doi.org/10.18632/oncotarget.6262
  46. Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, Shah KA, Whyman JD, Lansigan F, Hernandez-Ilizaliturri FJ, Lee LX, Barta SK, Melinamani S, Karmali R, Adeimy C, Smith S, Dalal N, Nabhan C, Peace D, Vose J,Evens AM, Shah N, Fenske TS, Zelenetz AD, Landsburg DJ, Howlett C, Mato A, Jaglal M, Chavez JC, Tsai JP,Reddy N, Li S, Handler C, Flowers CR, Cohen JB, Blum KA, Song K, Sun HL, Press O, Cassaday R, Jaso J,Medeiros LJ, Sohani AR, Abramson JS. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014; 124:2354-2361. https://doi.org/10.1182/blood-2014-05-578963
  47. Le Gouill S1, Talmant P, Touzeau C, Moreau A, Garand R, Juge-Morineau N, Gaillard F, Gastinne T, Milpied N, Moreau P, Harousseau JL, Avet-Loiseau H. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica. 2007;92(10):1335-1342. https://doi.org/10.3324/haematol.11305
  48. de Jongea AV, Roosmaa TJA, Houtenbosb I, Vasmeld WLE, van de Heme K, de Boerf JP, van Maaneng T, Lindauer-van der Werfh G, Beekerc A, Timmersi GJ, Schaarj CG, Soesank M, Poddighel PJ, de Jongm D, Chamuleaua MED. Diffuse large B-cell lymphoma with MYC gene rearrangements: Current perspective on treatment of diffuse large B-cell lymphoma with MYC gene rearrangements; case series and review of the literature. European Journal of Cancer. 2016;55:140-146. https://doi.org/10.1016/j.ejca.2015.12.001
  49. Gupta E, Accurso J, Sluzevich J, Menke DM, Tun HW. Excellent Outcome of Immunomodulation or Bruton’s Tyrosine Kinase Inhibition in Highly Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. Rare Tumors. 2015;7:6067. https://doi.org/10.4081/rt.2015.6067

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies